Advocate

Country: European Union

Language: Dutch

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

imidacloprid, moxidectin

Available from:

Bayer Animal Health GmbH

ATC code:

QP54AB52

INN (International Name):

imidacloprid, moxidectin

Therapeutic group:

Dogs; Cats; Ferrets

Therapeutic area:

Antiparasitaire producten, insecticiden en insectenwerende middelen

Therapeutic indications:

DogsFor honden die lijden aan of het risico bestaat van, gemengde parasitaire infecties:de behandeling en preventie van vlooien besmetting (Ctenocephalides felis),de behandeling van bijtende luizen (Trichodectes canis),de behandeling van oor mijt besmetting (Otodectes cynotis), sarcoptic schurft (veroorzaakt door Sarcoptes scabiei var. canis), demodicosis (veroorzaakt door Demodex canis),de preventie van hartworm ziekte (L3 en L4 larven van Dirofilaria immitis),de behandeling van circulerende microfilariae (Dirofilaria immitis),de behandeling van cutane dirofilariosis (volwassen stadia van Dirofilaria repens)de preventie van cutane dirofilariosis (L3 larven van Dirofilaria repens),de vermindering van circulerende microfilariae (Dirofilaria repens),de preventie van angiostrongylosis (L4 larven en jonge volwassenen van Angiostrongylus vasorum),de behandeling van Angiostrongylus vasorum en Crenosoma vulpis,de preventie van spirocercosis (Spirocerca lupi),de behandeling van Eucoleus (syn. Capillaria) boehmi (volwassenen),de behandeling van het oog worm Thelazia callipaeda (volwassenen),de behandeling van infecties met gastro-intestinale nematoden (L4 larven, jonge volwassenen en volwassenen van Toxocara canis, Ancylostoma caninum en Uncinaria stenocephala, volwassenen van Toxascaris leonina en Trichuris vulpis). Het product kan worden gebruikt als onderdeel van een behandelingsstrategie voor vlooienallergie dermatitis (FAD). CatsFor katten die lijden aan, of gevaar, gemengde parasitaire infecties:de behandeling en preventie van vlooien besmetting (Ctenocephalides felis),de behandeling van oor mijt besmetting (Otodectes cynotis),de behandeling van notoedric schurft (Notoedres cati),de behandeling van de lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (volwassenen),de preventie van lungworm ziekte (L3/L4 larven van Aelurostrongylus abstrusus),de behandeling van de lungworm Aelurostrongylus abstrusus (volwassenen),de behandeling van het oog worm Thelazia callipaeda (volwassenen),de preventie van hartworm ziekte (L3 en L4 larven van Dirofilaria immitis),de behandeling van infecties met gastro-intestinale nematoden (L4 larven, jonge volwassenen en volwassenen van Toxocara cati en Ancylostoma tubaeforme). Het product kan worden gebruikt als onderdeel van een behandelingsstrategie voor vlooienallergie dermatitis (FAD). FerretsFor fretten die lijden aan, of gevaar, gemengde parasitaire infecties:de behandeling en preventie van vlooien besmetting (Ctenocephalides felis),de preventie van hartworm ziekte (L3 en L4 larven van Dirofilaria immitis).

Product summary:

Revision: 23

Authorization status:

Erkende

Authorization date:

2003-04-02

Patient Information leaflet

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
Actuele informatie over dit geneesmiddel voor diergeneeskundig gebruik
is beschikbaar op de website
over diergeneesmiddelen.
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
Actuele informatie over dit geneesmiddel voor diergeneeskundig gebruik
is beschikbaar op de website
over diergeneesmiddelen.
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 31-01-2024
Public Assessment Report Public Assessment Report Bulgarian 29-01-2024
Patient Information leaflet Patient Information leaflet Spanish 31-01-2024
Public Assessment Report Public Assessment Report Spanish 29-01-2024
Patient Information leaflet Patient Information leaflet Czech 31-01-2024
Public Assessment Report Public Assessment Report Czech 29-01-2024
Patient Information leaflet Patient Information leaflet Danish 31-01-2024
Public Assessment Report Public Assessment Report Danish 29-01-2024
Patient Information leaflet Patient Information leaflet German 31-01-2024
Public Assessment Report Public Assessment Report German 29-01-2024
Patient Information leaflet Patient Information leaflet Estonian 31-01-2024
Public Assessment Report Public Assessment Report Estonian 29-01-2024
Patient Information leaflet Patient Information leaflet Greek 31-01-2024
Public Assessment Report Public Assessment Report Greek 29-01-2024
Patient Information leaflet Patient Information leaflet English 31-01-2024
Public Assessment Report Public Assessment Report English 29-01-2024
Patient Information leaflet Patient Information leaflet French 31-01-2024
Public Assessment Report Public Assessment Report French 29-01-2024
Patient Information leaflet Patient Information leaflet Italian 31-01-2024
Public Assessment Report Public Assessment Report Italian 29-01-2024
Patient Information leaflet Patient Information leaflet Latvian 31-01-2024
Public Assessment Report Public Assessment Report Latvian 29-01-2024
Patient Information leaflet Patient Information leaflet Lithuanian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 31-01-2024
Public Assessment Report Public Assessment Report Lithuanian 29-01-2024
Patient Information leaflet Patient Information leaflet Hungarian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 31-01-2024
Public Assessment Report Public Assessment Report Hungarian 29-01-2024
Patient Information leaflet Patient Information leaflet Maltese 31-01-2024
Public Assessment Report Public Assessment Report Maltese 29-01-2024
Patient Information leaflet Patient Information leaflet Polish 31-01-2024
Public Assessment Report Public Assessment Report Polish 29-01-2024
Patient Information leaflet Patient Information leaflet Portuguese 31-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 31-01-2024
Public Assessment Report Public Assessment Report Portuguese 29-01-2024
Patient Information leaflet Patient Information leaflet Romanian 31-01-2024
Public Assessment Report Public Assessment Report Romanian 29-01-2024
Patient Information leaflet Patient Information leaflet Slovak 31-01-2024
Public Assessment Report Public Assessment Report Slovak 29-01-2024
Patient Information leaflet Patient Information leaflet Slovenian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 31-01-2024
Public Assessment Report Public Assessment Report Slovenian 29-01-2024
Patient Information leaflet Patient Information leaflet Finnish 31-01-2024
Public Assessment Report Public Assessment Report Finnish 29-01-2024
Patient Information leaflet Patient Information leaflet Swedish 31-01-2024
Public Assessment Report Public Assessment Report Swedish 29-01-2024
Patient Information leaflet Patient Information leaflet Norwegian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 31-01-2024
Public Assessment Report Public Assessment Report Norwegian 29-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 31-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 31-01-2024
Public Assessment Report Public Assessment Report Icelandic 29-01-2024
Patient Information leaflet Patient Information leaflet Croatian 31-01-2024
Public Assessment Report Public Assessment Report Croatian 29-01-2024

Search alerts related to this product

View documents history